#USA #Terumo Medical #NaviCross #Peripheral Catheter #Somerset

Terumo Interventional Systems Unveils the R2P NaviCross Catheter

Terumo Interventional Systems (TIS), part of Terumo Corporation, has officially launched its latest product, the R2P™ NaviCross® peripheral support catheter, which is now available for commercial use in the United States. This new catheter bolsters the company's existing radial-to-peripheral (R2P) portfolio, providing healthcare professionals with a valuable tool for more complex medical procedures.

A Game-Changer for Peripheral Interventions

The introduction of the R2P NaviCross catheter signifies a significant advancement in the realm of vascular intervention. With a new length of 200 cm, this catheter is specifically engineered to optimize performance during procedures involving peripheral artery disease (PAD) and critical limb ischemia. The specialized design features a double-braided, stainless steel construction, which offers superior trackability and torque control.

Ghada Farah, Division President of Terumo Interventional Systems, expressed pride in the company's ability to respond to customer demands. "Our customers have been asking for a longer length, high-performance NaviCross support catheter, and I am proud to say we answered the need by delivering R2P NaviCross to the market," she stated. This launch enhances Terumo's position as a leader in radial access, particularly at a time when the demand for effective treatment of PAD continues to grow.

Enhancing Clinical Outcomes for Physicians

The R2P NaviCross catheter is designed for physicians performing percutaneous transluminal endovascular procedures from the radial artery. Dr. Michael J. Martinelli, Chief Medical Officer of Terumo Medical Corporation, highlighted the catheter's role in improving clinical outcomes. He stated, "The 200 cm length provides essential support for accessing and crossing both simple and complex lesions, significantly enhancing the ability of physicians to safely and efficiently complete more procedures from a radial approach."

Not only does the R2P NaviCross catheter serve as an effective tool for physicians, but it also complements an impressive lineup of devices in the R2P portfolio. This includes the R2P Destination Slender™ guiding sheath, the R2P SlenGuide™ guiding catheter, the R2P Misago® self-expanding peripheral stent, as well as the R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters.

Terumo's Commitment to Innovation

Terumo Interventional Systems has firmly established itself as a market leader in minimally invasive entry site management and therapeutic intervention. The company’s dedication to innovative research and development has resulted in a comprehensive product range that addresses advanced coronary, peripheral, and endovascular treatment needs. With strategic initiatives in Transradial Access, Complex Coronary Intervention, and Embolotherapy, Terumo continues to push the boundaries of what is possible in vascular intervention.

About Terumo Corporation: Founded over a century ago, Terumo has evolved from a thermometer manufacturer to a global leader in medical technology. Today, the organization operates in over 160 countries and regions, focusing on providing innovative healthcare solutions and products. With a workforce of more than 30,000 associates worldwide, Terumo remains committed to enhancing patient outcomes and supporting medical professionals across various fields.

As the launch of the R2P NaviCross catheter marks another milestone for Terumo, the company remains focused on its mission to improve healthcare and deliver value to patients, medical practitioners, and society as a whole.

For more detailed information about Terumo’s range of products and services, visit www.terumo.com.